» Articles » PMID: 25846127

A Low Protein Binding Cationic Poly(2-oxazoline) As Non-Viral Vector

Overview
Journal Macromol Biosci
Specialties Biochemistry
Biology
Date 2015 Apr 8
PMID 25846127
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Developing safe and efficient non-viral gene delivery systems remains a major challenge. We present a new cationic poly(2-oxazoline) (CPOx) block copolymer for gene therapy that was synthesized by sequential polymerization of non-ionic 2-methyl-2-oxazoline and a new 2-oxazoline monomer, 2-(N-methyl, N-Boc-amino)-methyl-2-oxazoline, followed by deprotection of the pendant secondary amine groups. Upon mixing with plasmid DNA (pDNA), CPOx forms small (diameter ≈80 nm) and narrowly dispersed polyplexes (PDI <0.2), which are stable upon dilution in saline and against thermal challenge. These polyplexes exhibited low plasma protein binding and very low cytotoxicity in vitro compared to the polyplexes of pDNA and poly(ethylene glycol)-b-poly(L-lysine) (PEG-b-PLL). CPOx/pDNA polyplexes at N/P = 5 bound considerably less plasma protein compared to polyplexes of PEG-b-PLL at the same N/P ratio. This is a unique aspect of the developed polyplexes emphasizing their potential for systemic delivery in vivo. The transfection efficiency of the polyplexes in B16 murine melanoma cells was low after 4 h, but increased significantly for 10 h exposure time, indicative of slow internalization of polyplexes. Addition of Pluronic P85 boosted the transfection using CPOx/pDNA polyplexes considerably. The low protein binding of CPOx/pDNA polyplexes is particularly interesting for the future development of targeted gene delivery.

Citing Articles

Ionic liquid-coated lipid nanoparticles increase siRNA uptake into CNS targets.

Khare P, Edgecomb S, Hamadani C, Conway J, Tanner E, Manickam D Nanoscale Adv. 2024; 6(7):1853-1873.

PMID: 38545295 PMC: 10964764. DOI: 10.1039/d3na00699a.


Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors.

Matos A, Peres C, Carreira B, Moura L, Acurcio R, Vogel T Adv Sci (Weinh). 2023; 10(25):e2300299.

PMID: 37434063 PMC: 10477894. DOI: 10.1002/advs.202300299.


Recent progress in polymeric gene vectors: Delivery mechanisms, molecular designs, and applications.

Xiu K, Zhang J, Xu J, Chen Y, Ma P Biophys Rev (Melville). 2023; 4(1):011313.

PMID: 37008888 PMC: 10062053. DOI: 10.1063/5.0123664.


PEG-Free Polyion Complex Nanocarriers for Brain-Derived Neurotrophic Factor.

Fay J, Lim C, Finkelstein A, Batrakova E, Kabanov A Pharmaceutics. 2022; 14(7).

PMID: 35890287 PMC: 9317007. DOI: 10.3390/pharmaceutics14071391.


Poly(2-oxazoline)- and Poly(2-oxazine)-Based Self-Assemblies, Polyplexes, and Drug Nanoformulations-An Update.

Zahoranova A, Luxenhofer R Adv Healthc Mater. 2021; 10(6):e2001382.

PMID: 33448122 PMC: 11468752. DOI: 10.1002/adhm.202001382.


References
1.
Nelson C, Kintzing J, Hanna A, Shannon J, Gupta M, Duvall C . Balancing cationic and hydrophobic content of PEGylated siRNA polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivo. ACS Nano. 2013; 7(10):8870-80. PMC: 3857137. DOI: 10.1021/nn403325f. View

2.
Gaertner F, Luxenhofer R, Blechert B, Jordan R, Essler M . Synthesis, biodistribution and excretion of radiolabeled poly(2-alkyl-2-oxazoline)s. J Control Release. 2007; 119(3):291-300. DOI: 10.1016/j.jconrel.2007.02.015. View

3.
Auman J . Gene therapy: Have the risks associated with viral vectors been solved?. Curr Opin Mol Ther. 2011; 12(6):637-8. View

4.
Varga C, Tedford N, Thomas M, Klibanov A, Griffith L, Lauffenburger D . Quantitative comparison of polyethylenimine formulations and adenoviral vectors in terms of intracellular gene delivery processes. Gene Ther. 2005; 12(13):1023-32. DOI: 10.1038/sj.gt.3302495. View

5.
Tuppurainen L, Sallinen H, Kokki E, Koponen J, Anttila M, Pulkkinen K . Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer. Hum Gene Ther Clin Dev. 2013; 24(1):29-37. DOI: 10.1089/humc.2013.006. View